Safety of etanercept in psoriasis: A critical review

Drug Safety

Volumn 29, Issue 8, 2006, Pages 675-685

  Sánchez Carazo, Jose L ^a   Santos, Laura Mahiques ^a   Martinez, Vicente Oliver ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; AMINOTRANSFERASE; AUTOANTIBODY; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; HYDROXYUREA; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERFERON; METHOTREXATE; NEUTRALIZING ANTIBODY; PSORALEN; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ANGIONEUROTIC EDEMA; APLASTIC ANEMIA; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG INFORMATION; DRUG MECHANISM; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL INFECTION; HEADACHE; HEPATITIS C; HUMAN; INFECTION; INJECTION SITE REACTION; INTRACELLULAR SPACE; LISTERIA MONOCYTOGENES; LUPUS ERYTHEMATOSUS; LYMPHOMA; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; PSORIASIS; PUVA; RASH; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; RISK BENEFIT ANALYSIS; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SKIN DEFECT; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; FEMALE; HUMANS; IMMUNOGLOBULIN G; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PSORIASIS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746825397     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629080-00004     Document Type: Review

References (86)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996 Jul; 14 (3): 485-96
2. Biondi Oriente C, Scarpa R, Pucino A, et al. Psoriasis and psoriatic arthritis: dermatological and rheumatological co-operative report. Acta Derm Venereol Suppl (Stockh) 1989; 146: 69-71
3. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 2000 Jul; 9 (7): 1511-22
4. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002 Jan; 46 (1): 1-23
5. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996 Jun 27; 334 (26): 1717-25
6. Mizutani H, Ohmoto Y, Mizutani T, et al. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 1997 Feb; 14 (2): 145-53
7. Mease PJ. Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002 Apr; 61 (4): 298-304
8. Gottlieb A. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol Ther 2004; 17 (5): 401-8
9. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999 Jan; 20 (1): 40-6
10. Roberts L, McColl GJ. Tumor necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern Med J 2004 Dec; 34 (12): 687-93
11. Chaudhari U, Romano P, Mulcahy D, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7
12. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol 2003; 49: S105-11
13. European Medicine Agency (EMEA). Summary of product characteristics: Enbrel® [online]. Available from URL: http://www.emea.eu.int [Accessed 2006 Jun 13]
14. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor IgG heavy chain chimeric protein as bivalent antagonist of TNF activity J Exp Med 1991 Dec 1; 174 (6): 1483-9
15. Klareskog L, Moreland LM, Cohen SB, et al. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy [abstract no. 150]. Arthritis Rheum 2001; 44 Suppl. 44: 77S
16. Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54: S92-100
17. Immunex Corp. Enbrel® (etanercept) [package insert]. Thousand Oaks (CA): Immunex Corp, 2005
18. Fleischman R. Safety and efficacy of disease modifying antirheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002; 25: 173-97
19. Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and inmunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor Fc fusion protein. Arch Dermatol 2001 Jul; 137 (7): 893-9
20. Skitta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000; 18 (4): 533-4
21. US Food and Drug Administration. Important drug warning [online]. Available from URL: www.fda.gov/medwatch/safety/1999/enbrel.htm [Accessed 2006 Jul 3]
22. Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 2004; 30: 237-55
23. Sociedad Española de Rheumatologia. Spanish registry for adverse events of biological therapies in rheumatic diseases [online]. Available from URL: http://biobadaser.ser.es [Accessed 2006 Jul 12]
24. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis alpha-neutralizing agent. N Engl J Med 2001 Oct 11; 345 (15): 1098-104
25. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infections as a complication of treatment with tumor necrosis factor alpha-neutralising agents. Arthritis Rheum 2003 Feb; 48 (2): 319-24
26. Phillips K, Husni ME, Karlson EW, et al. Experience with etanercept in an academic medical centre: are infection rates increased? Arthritis Rheum 2002 Feb; 47 (1): 17-21
27. Sabath DF. Serious infections reports with etanercept (Enbrel) therapy [abstract]. Ann Rheum Dis 2002; 61 Suppl. 1: 38S
28. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock from the tumor necrosis factor receptor: FC fusion protein. N Engl J Med 1996 Jun 27; 334 (26): 1697-702
29. Cohen RB, Dittrich KA. Anti-TNF therapy and malignancy: a critical review. Can J Gastroenterol 2001 Jun; 15 (6): 376-84
30. Letter of the Food and Drug Administration 2005 [online]. Available from URL: www.fda.gov/foi/warning_letters/g5207d.pdf [Accessed 2006 Jul 3]
31. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51
32. Askling J, Fored M, Baecklund E, et al. Hematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005 Oct; 64 (10): 1414-20
33. Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001; 117: 1531-7
34. Hannuksela-Svahn A, Pukkala E, Laara E, et al. Psoriasis, its treatement, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000; 114: 587-90
35. Tobin AM, Kirby B. TNFα inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005; 19 (1): 47-57
36. Hofman FM, Hinton DR, Johnson K, et al. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170: 607-12
37. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325: 467-72
38. Maimone D, Gregory S, Arnason BGW, et al. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991; 32: 67-74
39. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999; 53 (3): 457-65
40. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activity in two multiple sclerosis patients treated with the monoclonal anti tumour necrosis factor antibody cA2. Neurology 1996 Dec; 47 (6): 1531-4
41. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001 Sep; 44 (9): 1977-83
42. Sukal SA, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 2006; 54: 160-4
43. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumour necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001 Dec; 44 (12): 2862-9
44. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201-6
45. Levine B, Kalman J, Mayer L, et al. Elevated circulation levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41
46. Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303-12
47. Aikawa R, Nitta-Komatsubara Y, Kudoh S, et al. Reactive oxygen species induce cardiomyocyte apoptosis partly through TNF-alpha. Cytokine 2002; 18: 179-83
48. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-7
49. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999; 99: 3224-6
50. Bozkurtz B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation 2001; 103: 1044-7
51. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002 Dec; 86 (2-3): 123-30
52. Chung ES, Packer M, Lo KH. Randomized, double blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003 Jul 1; 107 (25): 3133-40
53. Kwon HJ, Cote TR, Cuffe MS. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003 May 20; 138 (10): 807-11
54. Wooten MD, Reddy GV, Johnson RD. Atrial fibrillation occuring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J 2000; 72 (12): 517-9
55. Pisetsky DS. Tumor necrosis factor α blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000 Nov; 43 (11): 2381-2
56. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999; 131: 634
57. Galaria NA, Werth VP, Schumacher HR. Leucocitoclastic vasculitis due to etanercept. J Rheumatol 2000; 27: 2041-4
58. Shakoor N, Michalska M, Harris CA, et al. Drug induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-80
59. Blemuink GS, ter Borg EJ, Ramslaar CG, et al. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 2001; 40: 1317-9
60. Kress D. Etanercept therapy improves symptoms and allows tapering of other medications in pediatric patients with moderate to severe psoriasis. J Am Acad Dermatol 2005; 54 (3 Suppl. 2): S126-8
61. Cather J, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg 2005 Mar; 24 (1): 37-45
62. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90
63. Lowell DJ, Gianinni EH, Reiff EH, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000 Mar 16; 342 (11): 763-9
64. Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078-82
65. Allen EJ, Hurley Y, Leonardi C. Etanercept therapy in psoriasis patients with hepatitis C. In: American Academy of Dermatology; 2005 Feb 18-22; Schaumburg (IL): American Academy of Dermatology, 2004
66. Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Heaptol 2005 Mar; 42 (3): 315-22
67. Chambers CD, Johnson D, Lyons Jones K. Safety of anti TNF alpha medications in pregnancy [abstract]. In: American Academy of Dermatology; 2005; New Orleans. Schaumburg (IL): American Academy of Dermatology, 2004
68. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003; 49: 87-97
69. Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-55
70. Lebwohl M, Christophers E, Langley E, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-37
71. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-33
72. Mease PJ, Glandman DD, Keystone ED. Alefacept in psoriatic arthritis study group. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006 May; 54 (5): 1638-45
73. Ortonne JP, Khemis A, Koo JY, et al. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2005 Sep; 19 (5): 556-63
74. Leonardo CL. Efalizumab: an overview. J Am Acad Dermatol 2003; 49: 98-104
75. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-13
76. Gottlieb AB, Millar B, Lowe N, et al. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 2003; 7 (3): 198-207
77. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073-80
78. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003; 49: 112-7
79. Gottlieb AB, Chaudary U, Mulcahy LD, et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48: 829-835
80. Delaunay C, Farrenq V, Marini-Portugal A, et al. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005 Nov; 32 (11): 2183-5.
81. European Medicines Agency (EMEA). Remicade: European public assessment report [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/ EPAR/remicade/remicade.htm [Accessed 2006 Jul 12]
82. Wallis M, Brother S, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38 (1): 1261-5
83. Remicade® (infliximab) for IV injection [online]. Available from URL: http://www.fda.gov/cder/foi/label/2002/inflcen022702LB.pdf [Accessed 2006 Jul 12]
84. Wallis M, Brother S, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38 (1): 1261-5
85. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet - a light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA follow-up study. J Natl Cancer Inst 1998; 90: 1278-84
86. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). New Engl J Med 1997; 336: 1041-45